I. What Makes Fujian Pharmaceuticals Worth Studying Is One End Oldest, One End Newest

To describe a province's pharmaceutical industry, the usual approach is to list some output figures and name a few drugmakers. But what truly sets Fujian apart is not its scale; it is the contrast between its two ends.

One end is the oldest. Zhangzhou in southern Fujian guards Pien Tze Huang, a formula whose composition and craft have been handed down for centuries and remain a state-secret-protected Chinese medicine to this day, with even its ingredient ratios beyond outsiders' reach. The other end is the newest. Across the strait, Xiamen makes long-acting interferon, domestic vaccines, and tumor molecular diagnostic kits, all frontier biopharmaceutical tracks that have only risen in China over the past decade or two. One guards an inherited secret recipe; the other bets on the most advanced biotechnology. The two are barely two hundred kilometers apart, yet they belong to the two ends of pharmaceuticals separated by the greatest span of time.

That is why the Tianxia Gongchang Industry Research Institute singles out Fujian pharmaceuticals. Most major pharmaceutical provinces are strong in chemical APIs or in scaling generics; Fujian instead walks on two legs, one ancient formula and one new biomedical city. Under the provincial plan, Xiamen and Fuzhou are set as innovation core areas, with Zhangzhou, Sanming, Ningde, Putian, Longyan, Nanping, and Quanzhou as industrial agglomeration zones, forming a "two cores, many zones" layout, and a target for the province's pharmaceutical industry revenue to reach 120 billion yuan by 2025. This report endorses no investment judgment; it simply maps Fujian's pharmaceutical chain, driven by two cores of traditional Chinese medicine heritage and Xiamen biopharma, and honestly notes the difficulties each faces.

II. Zhangzhou: Pien Tze Huang Guards a Formula That Cannot Be Passed On

To understand the oldest end of Fujian pharmaceuticals, begin with Zhangzhou's Pien Tze Huang.

Pien Tze Huang is a Chinese patent medicine handed down for centuries; its formula and production craft remain classified at the state's top-secret level. It is a first-class state-protected Chinese medicine, and its traditional craft is listed in the national intangible cultural heritage roster. Such a level of secrecy is extremely rare across the entire Chinese-medicine industry. It means Pien Tze Huang has no true competing equivalent; its moat is not built from capacity or distribution, but written into a formula outsiders cannot obtain.

This ancient formula supports a leading Chinese-medicine enterprise. Zhangzhou Pien Tze Huang Pharmaceutical reported 2023 revenue of about 10 billion yuan, up roughly 15 percent year on year, with net profit attributable to shareholders of about 2.8 billion yuan. Its flagship product has for years ranked among the top single-variety Chinese patent medicine exports and is one of the higher-valued brands among China's time-honored marques. In short, this oldest end of Fujian pharmaceuticals is not a cluster of medicine factories, but a single proprietary formula plus one company that has worked around it for centuries; its weight rests almost entirely on that recipe that cannot be passed on.

III. Xiamen: From a Single Interferon to a New Biomedical City

The newest end of Fujian pharmaceuticals is in Xiamen.

Unlike Zhangzhou guarding its formula, Xiamen took another path: building, in some two decades, a new biomedical city centered on Haicang. By 2023, Xiamen's Haicang biomedical port had gathered more than 470 biopharmaceutical firms, with an industry scale above 35 billion yuan, forming a cluster characterized by in vitro diagnostics, medical devices, new-drug R&D, and novel vaccines. What is most worth watching about this new city is that it has raised a leader in each of several niche tracks.

One is Amoytop Biotech, which makes long-acting protein drugs. It listed on the STAR Market in 2020 as Xiamen's first STAR-listed company. Its core product, a long-acting interferon for therapeutic use developed over many years, alone contributed over 80 percent of company revenue in 2023; that year revenue was about 2.1 billion yuan, up around 37 percent, with net profit of about 550 million yuan, nearly doubling. This is a textbook case of one drug carrying a company.

Another is Wantai Biopharm, which makes vaccines and diagnostic kits; it co-built a national engineering technology research center for infectious-disease diagnostics and vaccines with Xiamen University, and its domestic bivalent cervical-cancer vaccine was the first of its kind approved in China. A third is Amoy Diagnostics, focused on companion diagnostics for tumor precision medicine, whose microsatellite-instability test was approved in 2023 as the first companion-diagnostic certificate for pan-cancer immunotherapy. Diagnostic kits, vaccines, long-acting protein drugs, tumor molecular diagnostics: what makes Xiamen's end special is not how large any single figure is, but that it has nurtured a presentable company in each of several hard biopharmaceutical niches.

IV. Fuzhou and Sanming: The APIs and Formulations Filling the Middle

Beyond the two cores, the middle stretch of Fujian's pharmaceutical chain rests on the APIs and formulations of Fuzhou and Sanming.

This stretch is neither as proprietary as Zhangzhou's formula nor as frontier as Xiamen's vaccines; it does more basic work: antibiotic APIs and various formulations. Fuzhou's Neptunus Fuyao makes tablets, capsules, and APIs covering anti-infective varieties such as cephalosporins and penicillins; Fukang Pharmaceutical, around Sanming and Fuzhou, is strong in specialty APIs and pharmaceutical intermediates, with its antibiotic APIs and cephalosporin formulations passing the new national good-manufacturing-practice standards, and some products certified by the EU, the United States, and Japan, giving it export credentials.

The value of this stretch lies not in being eye-catching, but in keeping Fujian's chain relatively complete: from the most basic APIs and intermediates, to formulations, up to chemical and biological drugs, many links can be connected within the province. Whether a province's pharmaceutical manufacturing can stand firm often depends not only on whether it has a few star companies, but on how thick this unremarkable API-and-formulation base in the middle is. The Fuzhou-Sanming stretch is precisely the middle that links Fujian pharmaceuticals' two striking cores.

V. Two Cores and a Middle: A Chain Weak at Neither End

Putting Zhangzhou, Xiamen, Fuzhou, and Sanming together, the shape of Fujian's pharmaceutical chain becomes clear.

It is not a conventional chain laid straight from API to formulation, but a chain with a strength standing at each end and APIs and formulations filling the middle: at the Zhangzhou end, a proprietary ancient formula of a time-honored Chinese-medicine marque; at the Xiamen end, several niche biopharmaceutical leaders; in between, Fuzhou and Sanming continuing the chain with APIs and formulations. Chinese medicine, biopharmaceuticals, chemical drugs, high-end medical devices: Fujian can find a foothold for most of these directions within the province. This "two cores plus a middle" shape means Fujian pharmaceuticals need not stake everything on one class of drug.

This too is what sets Fujian apart from many pharmaceutical regions. Many regions specialize in chemical APIs, or in generics, or in one class of Chinese medicine; Fujian instead makes both the most traditional time-honored Chinese medicine and the most frontier biopharmaceuticals real within the same province. The chain's value lies not in every segment leading nationally, but in each end holding something irreplaceable, a formula outsiders cannot obtain and a biomedical city gathered over twenty years, with APIs and formulations connecting them in between.

VI. The Transition Questions: Single-Product Reliance, Price Cycles, and the New City's Long Road

Neither end of the chain is weak, but as Fujian pharmaceuticals reach today, each faces concrete questions of its own.

The question at the Zhangzhou end is over-reliance on a single product. Pien Tze Huang's moat comes from that secret formula, but it also means the company's lifeline hinges on this one medicine; if its capacity, pricing, or raw-material supply swings, the whole company is pulled along. How to broaden the product line while guarding the ancient formula is a question this leading Chinese-medicine maker cannot avoid.

The question at the Xiamen end is the price cycles and long road of new tracks. Biopharmaceuticals look glamorous yet are least able to withstand the back-and-forth of policy and competition. Domestic vaccines, for instance, can see revenue swing sharply once centralized procurement cuts prices or peers expand capacity; Wantai Biopharm's 2023 revenue, nearly halved from the prior year, is a portrait of such swings. Tracks like long-acting protein drugs and tumor diagnostics demand heavy R&D and have long payback periods; Xiamen's new biomedical city still has a fair road ahead to reach stable profitability.

The third question is the added value of the middle. The APIs and formulations of Fuzhou and Sanming do relatively basic work, with prices pulled by raw-material cycles and peer competition, leaving limited room to merely compete on capacity. Whether it can move from bulk APIs toward specialty APIs and high-end formulations decides whether this middle earns hard processing money or commands a technology premium.

For upstream suppliers serving Fujian's pharmaceutical manufacturing, whether sales teams in APIs, pharmaceutical intermediates, drug-production equipment, diagnostic reagents and consumables, or packaging materials, Tianxia Gongchang lets them filter Fujian pharmaceutical-manufacturing factory directories and decision-maker contacts along the two dimensions of region and industry, turning customer development from asking around one by one into following a map.

VII. The Institute's Assessment

What is most worth remembering about Fujian pharmaceuticals is the contrast between its two ends: Zhangzhou guards Pien Tze Huang, a formula handed down for centuries that outsiders cannot obtain, while Xiamen has gathered in some twenty years a new biomedical city making vaccines, long-acting interferon, and tumor diagnostic kits. One is a moat brewed by time, the other a moat built by technology, with Fuzhou and Sanming's APIs and formulations continuing the chain in between. For a province to make both the longest-spanning ends of pharmaceuticals real is itself uncommon.

But the strength at each end corresponds to a weakness at each end. Zhangzhou's difficulty lies in staking its lifeline on a single medicine; Xiamen's lies in the price swings and long payback of new tracks. The next stage for Fujian pharmaceuticals will be decided not by how many more boxes of Pien Tze Huang it can sell or how many more vaccine doses it can deliver, but by whether the Zhangzhou end can widen a single product's moat into a product line's moat, and whether the Xiamen end can carry its cash-burning new tracks to stable profit. The Tianxia Gongchang Industry Research Institute's assessment is this: the foundations at both ends are distinctive enough, and rare is this coexistence of old and new; but turning one ancient formula into a broader product matrix, and one new city into a continuously profitable industry, are two questions no one can answer on Fujian's behalf.

Data Sources

  • Tianxia Gongchang (Fujian pharmaceutical-manufacturing factory directory and industry data)
  • People's Government of Fujian Province, Fujian Department of Industry and Information Technology: implementation plan for high-quality development of the biopharmaceutical industry, the "two cores, many zones" layout, and the 2025 target of 120 billion yuan in provincial pharmaceutical-industry revenue
  • Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. 2023 annual report and board work report: revenue and net profit, Pien Tze Huang as a first-class state-protected Chinese medicine and its single-variety Chinese-patent-medicine export standing
  • Fujian provincial government portal, Fujian Medical Products Administration: enterprise count and industry scale of Xiamen's Haicang biomedical port, and the in-vitro-diagnostics and novel-vaccine cluster characteristics
  • Xiamen Amoytop Biotech Co., Ltd. 2023 annual report: revenue and net profit, the revenue share of the long-acting interferon, and status as Xiamen's first STAR Market listed company
  • Beijing Wantai Biological Pharmacy 2023 annual report: revenue change, the domestic bivalent cervical-cancer vaccine as the first of its kind approved in China, and the national engineering technology research center co-built with Xiamen University
  • Xiamen Amoy Diagnostics Co., Ltd. annual reports and industry research: standing in tumor precision-medicine companion diagnostics, and the microsatellite-instability product approved as the first companion diagnostic for pan-cancer immunotherapy
  • Public materials of Fuzhou Neptunus Fuyao Pharmaceutical Co., Ltd. and Fujian Fukang Pharmaceutical Co., Ltd.: cephalosporin and penicillin formulations and API varieties, and domestic and international quality certifications and export credentials for antibiotic APIs and cephalosporin formulations